Voronoi, Inc.
KOSDAQ-listed drug developer using its VORONOMICS AI platform to create targeted therapies for lung and breast cancer for licensing out.
As of 2026-10-10, Voronoi, Inc. has 25 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2015 and listed on KOSDAQ in 2022, Voronoi is a drug development company focused on early-stage clinical development (Phase 1-2). It develops precision kinase-targeted therapies for cancers such as lung and breast cancer, discovering candidates through its proprietary AI platform VORONOMICS® along with its medicinal chemistry institute, bio institute, animal testing center, and AI institute. The company does not manufacture finished drug products; instead it conducts early clinical trials on its own candidates to verify efficacy in humans and then pursues global out-licensing (License-Out).
Clinical trials
data.go.kr2 MFDS clinical trial authorisations · 2019–2023 (Phase 1 2)
- Phase 1VRN110755 캡슐2023-10-26
11 trial sites
- Phase 1VN100722019-08-13
5 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Recruiting · 2026-06 · NCT07550946
Phase 1 · Completed · 2025-08 · NCT07141381
Phase 1 · Recruiting · 2025-02 · NCT06806982
Phase 1/2 · Recruiting · 2024-03 · NCT07699328
R&D and key agreements
Source: DART corporate disclosureKinase 정밀표적치료제 파이프라인(세부 물질명 원문 미기재) · 폐암, 유방암 등 항암 · 초기임상(1~2상) 직접수행 후 기술이전 · Developed using proprietary AI platform VORONOMICS®
Key disclosures
KRX KIND via OpenDARTShow 19 more events
Publications
PubMed · affiliation-matched- Author Correction: p21-activated kinase 4 counteracts PKA-dependent lipolysis by phosphorylating FABP4 and HSL.
Nature metabolism · 2026-09 · Yu HC, Jeon YG, Na AY 외 10
- Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.
Cancer research · 2026-02 · Junttila MR, Repellin CE, Salaniwal S 외 28
- Publisher Correction: Digital removal of dermal denticle layer using geometric AI from 3D CT scans of shark craniofacial structures enhances anatomical precision.
Scientific reports · 2025-07 · Kim SW, Yuen AHL, Kim HW 외 17
- Identifying Anti-cancer Effects and Exploring the Mechanism of an MPS1/TTK Inhibitor in Gastric Cancer.
Cancer research and treatment · 2025-07 · Kim E, Kwon WS, Kim TS 외 3
- Digital removal of dermal denticle layer using geometric AI from 3D CT scans of shark craniofacial structures enhances anatomical precision.
Scientific reports · 2025-06 · Kim SW, Yuen AHL, Kim HW 외 17
- p21-activated kinase 4 counteracts PKA-dependent lipolysis by phosphorylating FABP4 and HSL.
Nature metabolism · 2024-01 · Yu HC, Jeon YG, Na AY 외 10
- Author Correction: p21-activated kinase 4 suppresses fatty acid β-oxidation and ketogenesis by phosphorylating NCoR1.
Nature communications · 2023-11 · Shi MY, Yu HC, Han CY 외 8
- Sesamin ameliorates lipotoxicity and lipid accumulation through the activation of the estrogen receptor alpha signaling pathway.
Biochemical pharmacology · 2023-10 · Pham TH, Lee GH, Jin SW 외 8
- p21-activated kinase 4 suppresses fatty acid β-oxidation and ketogenesis by phosphorylating NCoR1.
Nature communications · 2023-08 · Shi MY, Yu HC, Han CY 외 8
- Ethyl Gallate Isolated from Castanopsis cuspidata var. sieboldii Branches Inhibits Melanogenesis and Promotes Autophagy in B16F10 Cells.
Antioxidants (Basel, Switzerland) · 2023-01 · Choi MH, Yang SH, Kim DS 외 2
Show 15 more publications
- FRTX-02, a selective and potent inhibitor of DYRK1A, modulates inflammatory pathways in mouse models of psoriasis and atopic dermatitis.
Journal of translational autoimmunity · 2023-01 · Kim S, Ko E, Choi HG 외 4
- Benchmark dataset for the Voronoi diagram of 3D spherical balls.
Data in brief · 2022-12 · Song C, Lee M, Choi S 외 1
- Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer.
Experimental & molecular medicine · 2022-09 · Hwang WC, Song D, Lee H 외 6
- Puerarin attenuates hepatic steatosis via G-protein-coupled estrogen receptor-mediated calcium and SIRT1 signaling pathways.
Phytotherapy research : PTR · 2022-09 · Pham TH, Lee GH, Jin SW 외 4
- Nomilin from Yuzu Seed Has In Vitro Antioxidant Activity and Downregulates Melanogenesis in B16F10 Melanoma Cells through the PKA/CREB Signaling Pathway.
Antioxidants (Basel, Switzerland) · 2022-08 · Choi MH, Yang SH, Kim ND 외 1
- p21-activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2-related factor 2 phosphorylation.
Hepatology (Baltimore, Md.) · 2022-08 · Mao Y, Han CY, Hao L 외 11
- A Dynamic Substrate Pool Revealed by cryo-EM of a Lipid-Preserved Respiratory Supercomplex.
Antioxidants & redox signaling · 2022-04 · Jeon TJ, Lee SG, Yoo SH 외 8
- Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Molecular cancer therapeutics · 2022-02 · Bahcall M, Paweletz CP, Kuang Y 외 15
- Structural basis for SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins.
Acta crystallographica. Section D, Structural biology · 2021-11 · Kim DG, Baek I, Lee Y 외 8
- Novel Quercetin Derivative of 3,7-Dioleylquercetin Shows Less Toxicity and Highly Potent Tyrosinase Inhibition Activity.
International journal of molecular sciences · 2021-04 · Choi MH, Yang SH, Kim DS 외 3
- Development of a miRNA-controlled dual-sensing system and its application for targeting miR-21 signaling in tumorigenesis.
Experimental & molecular medicine · 2020-12 · Seo Y, Kim SS, Kim N 외 3
- Catechol inhibits epidermal growth factor-induced epithelial-to-mesenchymal transition and stem cell-like properties in hepatocellular carcinoma cells.
Scientific reports · 2020-05 · Lim WC, Kim H, Kim YJ 외 3
- Benchmark dataset for the convex hull of 2D disks.
Data in brief · 2019-12 · Song C, Ryu J, Kim DS
- Optimal ligand descriptor for pocket recognition based on the Beta-shape.
PloS one · 2015-01 · Kim JK, Won CI, Cha J 외 2
- Pocket extraction on proteins via the Voronoi diagram of spheres.
Journal of molecular graphics & modelling · 2008-04 · Kim D, Cho CH, Cho Y 외 3
Patents
KIPRIS · applicant-matchedPublished · 2026-02 · Application 1020260023333
Published · 2025-10 · Application 1020250158404
PCT · Published · 2025-10 · Application PCT/KR2025/017365
Published · 2025-08 · Application 1020250122729
TW · Published · 2025-08 · Application 114133251
PCT · Published · 2025-08 · Application PCT/KR2025/013323
Published · 2025-08 · Application 1020250121400
Published · 2025-07 · Application 1020250098585
PCT · Published · 2025-07 · Application PCT/KR2025/095464
Published · 2025-03 · Application 1020250034304
Show 154 more patents
TW · Published · 2025-03 · Application 114109946
PCT · Published · 2025-03 · Application PCT/KR2025/003462
TW · Published · 2025-03 · Application 114108722
Published · 2025-03 · Application 1020250029959
PCT · Published · 2025-03 · Application PCT/KR2025/003049
TW · Published · 2024-11 · Application 113142789
Published · 2024-11 · Application 1020240156559
PCT · Published · 2024-11 · Application PCT/KR2024/017446
US · Published · 2024-09 · Application 18887279
Published · 2024-07 · Application 1020240101088
US · Registered · 2024-06 · Application 18731285
TW · Published · 2024-04 · Application 113113572
Published · 2024-04 · Application 1020240048303
PCT · Published · 2024-04 · Application PCT/KR2024/004758
Published · 2024-03 · Application 1020240035842
Published · 2024-02 · Application 1020240028823
PCT · Published · 2024-02 · Application PCT/KR2024/002588
US · Registered · 2024-01 · Application 18414371
Published · 2023-12 · Application 1020230189595
PCT · Published · 2023-12 · Application PCT/KR2023/021452
Rejected · 2023-12 · Application 1020230188802
Published · 2023-11 · Application 1020230163623
Published · 2023-11 · Application 1020230157401
US · Published · 2023-11 · Application 19123737
EP · Published · 2023-11 · Application 23891981.5
PCT · Published · 2023-11 · Application PCT/KR2023/018285
Published · 2023-11 · Application 1020257017772
PCT · Published · 2023-11 · Application PCT/KR2023/017405
EP · Published · 2023-11 · Application 23886319.5
US · Registered · 2023-10 · Application 18486783
US · Published · 2023-09 · Application 18474027
Published · 2023-09 · Application 1020230124264
Published · 2023-09 · Application 1020230119065
Registered · 2023-08 · Application 1020230112461
PCT · Published · 2023-06 · Application PCT/KR2023/008973
Withdrawn · 2023-05 · Application 1020247038560
US · Published · 2023-05 · Application 18868557
PCT · Published · 2023-05 · Application PCT/KR2023/007286
EP · Published · 2023-05 · Application 23812204.8
PCT · Published · 2023-05 · Application PCT/IB2023/000256
PCT · Published · 2023-05 · Application PCT/IB2023/000286
Withdrawn · 2023-04 · Application 1020230055923
TW · Published · 2023-04 · Application 112116031
PCT · Published · 2023-04 · Application PCT/KR2023/005855
TW · Registered · 2023-04 · Application 112112931
Registered · 2023-04 · Application 1020230045001
US · Published · 2023-04 · Application 18692229
EP · Published · 2023-04 · Application 23784997.1
PCT · Published · 2023-04 · Application PCT/KR2023/004601
PCT · Published · 2023-03 · Application PCT/IB2023/000184
Rejected · 2022-12 · Application 1020220185795
PCT · Published · 2022-12 · Application PCT/KR2022/019664
Published · 2022-10 · Application 1020220141774
TW · Published · 2022-10 · Application 111141253
US · Published · 2022-10 · Application 18705952
EP · Published · 2022-10 · Application 22887724.7
PCT · Published · 2022-10 · Application PCT/KR2022/016766
Published · 2022-10 · Application 1020220136509
US · Published · 2022-10 · Application 18702203
EP · Published · 2022-10 · Application 22884103.7
PCT · Published · 2022-10 · Application PCT/KR2022/016188
PCT · Published · 2022-08 · Application PCT/KR2022/013004
Withdrawn · 2022-07 · Application 1020247005140
Withdrawn · 2022-06 · Application 1020220079243
TW · Registered · 2022-05 · Application 111118417
Registered · 2022-05 · Application 1020220059638
US · Registered · 2022-05 · Application 17927324
EP · Published · 2022-05 · Application 22793620.0
PCT · Published · 2022-05 · Application PCT/KR2022/006994
Published · 2022-04 · Application 1020220044202
Withdrawn · 2022-04 · Application 1020220044034
US · Published · 2022-04 · Application 18559542
US · Published · 2022-04 · Application 18556883
EP · Published · 2022-04 · Application 22799010.8
EP · Published · 2022-04 · Application 22791938.8
PCT · Published · 2022-04 · Application PCT/KR2022/005163
PCT · Published · 2022-04 · Application PCT/KR2022/005144
Withdrawn · 2022-03 · Application 1020220039695
US · Registered · 2022-03 · Application 17701478
Withdrawn · 2022-01 · Application 1020220001748
PCT · Published · 2022-01 · Application PCT/KR2022/000172
Published · 2021-12 · Application 1020210191079
US · Published · 2021-12 · Application 18259696
EP · Published · 2021-12 · Application 21915825.0
PCT · Published · 2021-12 · Application PCT/KR2021/020165
Withdrawn · 2021-12 · Application 1020210183147
PCT · Published · 2021-12 · Application PCT/KR2021/019439
Withdrawn · 2021-12 · Application 1020210179109
PCT · Published · 2021-12 · Application PCT/KR2021/018956
US · Published · 2021-12 · Application 17643554
EP · Published · 2021-12 · Application 21902773.7
US · Registered · 2021-11 · Application 17521711
Registered · 2021-10 · Application 1020210141386
Rejected · 2021-10 · Application 1020210140107
Published · 2021-09 · Application 1020237006462
US · Published · 2021-09 · Application 18026793
EP · Published · 2021-09 · Application 21869818.1
TW · Published · 2021-09 · Application 110134885
Withdrawn · 2021-07 · Application 1020210092507
Registered · 2021-03 · Application 1020210032594
Withdrawn · 2021-02 · Application 1020210019532
Rejected · 2020-12 · Application 1020200171340
TW · Registered · 2020-09 · Application 109132472
Rejected · 2020-05 · Application 1020200061765
US · Published · 2020-05 · Application 17595655
Registered · 2020-05 · Application 1020200060874
CN · Published · 2020-05 · Application 202080037699.2
US · Registered · 2020-05 · Application 17612757
EP · Published · 2020-05 · Application 20808953.2
Withdrawn · 2020-05 · Application 1020200059241
US · Published · 2020-05 · Application 17610255
EP · Published · 2020-05 · Application 20810762.3
US · Registered · 2020-05 · Application 17610066
EP · Published · 2020-05 · Application 20804945.2
Withdrawn · 2020-04 · Application 1020200052053
Registered · 2020-03 · Application 1020200033737
CN · Published · 2020-03 · Application 202210215237.6
CN · Published · 2020-03 · Application 202080022186.4
US · Registered · 2020-03 · Application 17440630
EP · Published · 2020-03 · Application 25174837.2
EP · Registered · 2020-03 · Application 20774059.8
PCT · Published · 2020-03 · Application PCT/KR2020/095044
Rejected · 2020-03 · Application 1020200031450
CN · Published · 2020-03 · Application 202080020325.X
US · Published · 2020-03 · Application 17438341
EP · Published · 2020-03 · Application 20768933.2
Withdrawn · 2020-02 · Application 1020200025310
Registered · 2020-01 · Application 1020200007476
Rejected · 2020-01 · Application 1020200007245
CN · Published · 2020-01 · Application 202080020054.8
CN · Published · 2020-01 · Application 202080022151.0
US · Registered · 2020-01 · Application 17423186
US · Published · 2020-01 · Application 17423728
EP · Registered · 2020-01 · Application 20741744.5
EP · Published · 2020-01 · Application 20742007.6
Registered · 2019-12 · Application 1020190179908
CN · Published · 2019-11 · Application 201980075997.8
US · Registered · 2019-11 · Application 17293292
EP · Registered · 2019-11 · Application 19886687.3
CN · Published · 2019-10 · Application 201980068512.2
US · Registered · 2019-10 · Application 17283441
EP · Registered · 2019-10 · Application 19874207.4
Rejected · 2019-07 · Application 1020190081308
US · Published · 2019-07 · Application 17258667
Withdrawn · 2019-05 · Application 1020190062722
Withdrawn · 2019-05 · Application 1020190062721
Rejected · 2019-05 · Application 1020190059502
Withdrawn · 2019-05 · Application 1020190057638
Registered · 2019-03 · Application 1020190028946
Registered · 2019-03 · Application 1020190028954
Withdrawn · 2019-02 · Application 1020190024129
Withdrawn · 2019-01 · Application 1020190005406
Withdrawn · 2019-01 · Application 1020190004110
Withdrawn · 2018-01 · Application 1020180002309
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot56
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Voronoi, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition